ÂÜÀòÂÒÂ×

John David Konda is part of the antibody discovery team supporting antibody generation at AlivaMab Discovery Services (ADS). He has over 10 years of research experience. John obtained his Ph.D. in molecular medicine from the University of Turin, Italy, where he specialized in cancer research. He studied the HSP27 protein that makes tumor cells susceptible to therapeutics especially working with resistant oncogene-addicted cells. He conducted postdoctoral research in the Department of Medicine and Surgery at McGill University, Montreal, Canada, during which he investigated a novel pancreatic and hepatic stellates cells crosstalk mechanism via exosomes that identified IMP-1 protein as a participant in the early stages of liver metastasis. Prior to joining ADS, he was a postdoctoral fellow at MaRS Centre, Princess Margaret Cancer Centre / University Health Network Toronto, Canada, where he studied multiple myeloma and its impact on the differentiation of hematological cancer stem cells and developed novel therapeutics. He is experienced in antibody generation, hybridoma technology, animal models, mice immunizations, molecular and cell biology, flow cytometry, cell sorting, and exosome biology.